Change is constant in regulated industries—but how that change is managed is becoming a growing focus for regulators in 2026.
The U.S. Food and Drug Administration is placing increased scrutiny on change control systems across pharmaceutical, biotechnology, and medical device organizations. As companies adopt new technologies, scale manufacturing, and adjust supply chains, regulators are evaluating whether changes are properly assessed, documented, and controlled.
In many recent inspections, poorly managed change control has been linked to broader quality system failures.
Why Change Control Is a Regulatory Priority
Change control ensures that any modification—whether to processes, systems, equipment, suppliers, or documentation—is evaluated for its potential impact on product quality and compliance.
Without a structured approach, even small changes can introduce unintended risks. Regulators expect organizations to fully understand and document the impact of each change before implementation.
In 2026, this expectation is expanding as organizations become more complex and interconnected.
What FDA Inspectors Are Looking For
During inspections, the FDA is focusing on how changes are managed across the entire lifecycle—not just how they are documented.
Key areas of focus include:
- Impact assessments, evaluating how changes affect quality, safety, and regulatory filings
- Cross-functional review and approval, ensuring quality, regulatory, and technical teams are aligned
- Linkage to validation and verification activities, confirming that changes are properly tested
- Integration with CAPA and deviation systems, ensuring changes address root causes where applicable
- Timeliness and completeness of documentation, including approvals and implementation records
These elements must demonstrate that changes are controlled, justified, and traceable.
Common Gaps Identified During Inspections
Despite having formal procedures in place, many organizations struggle with execution.
Common findings include:
- Incomplete or superficial impact assessments
- Implementation of changes before formal approval
- Lack of coordination between departments
- Missing validation or verification activities
- Poor documentation of decisions and rationale
These gaps can lead to inconsistencies in operations and raise concerns about overall system control.
The Risk of Uncontrolled Change
Uncontrolled or poorly managed changes can have serious consequences, including product quality issues, batch failures, or regulatory noncompliance.
From a regulatory standpoint, these issues may result in Form 483 observations, Warning Letters, or delays in approvals.
More importantly, they can undermine confidence in an organization’s ability to maintain control over its processes.
Moving Toward Proactive Change Management
To align with evolving expectations, organizations must treat change control as a proactive, risk-based process.
This includes conducting thorough impact assessments, ensuring cross-functional collaboration, and maintaining clear documentation throughout the change lifecycle.
Organizations should also implement monitoring mechanisms to evaluate the effectiveness of changes after implementation.
Embedding change control into daily operations helps ensure that all modifications are managed consistently and compliantly.
How EMMA International Supports Change Control and Compliance
At EMMA International, we support organizations in strengthening change control systems and aligning them with FDA expectations.
Our teams help design risk-based frameworks, improve documentation practices, integrate change control with quality systems, and ensure readiness for regulatory inspections.
As organizations continue to evolve, those that manage change effectively will be better positioned to maintain compliance, reduce risk, and sustain operational performance.
References
U.S. Food and Drug Administration. Quality System Regulation (21 CFR Part 820).
U.S. Food and Drug Administration. Process Validation Guidance.
International Council for Harmonisation (ICH). Q10 Pharmaceutical Quality System.
